
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>ACG Clinical Guideline: Chronic Pancreatitis</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>ACG Clinical Guideline: Chronic Pancreatitis</strong></summary>
            <div>
                <ul><li>Journal: Am J Gastroenterol</li><li>Publication Date: February 5, 2020</li><li>DOI: https://doi.org/10.14309/ajg.0000000000000535</li><li>Target Audience: General Gastroenterologists</li><li>Purpose: Provide evidence-based, practical approach to CP diagnosis &amp; management.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What is the primary imaging modality recommended as first-line for diagnosing Chronic Pancreatitis (CP)?</li><li>2. According to the guideline, what percentage of pancreatic function loss typically results in clinically apparent symptoms of Exocrine Pancreatic Insufficiency (EPI)?</li><li>3. Which intervention has shown superior long-term pain relief for obstructive CP when first-line endoscopic approaches have failed: continued endoscopic therapy or surgical intervention?</li><li>4. What is the approximate lifetime risk of developing pancreatic adenocarcinoma in patients with well-characterized genetic polymorphisms predisposing them to CP?</li><li>5. Is pancreatic enzyme replacement therapy (PERT) recommended primarily for pain control or for improving complications of malnutrition in patients with CP and Exocrine Pancreatic Insufficiency (EPI)?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Chronic Pancreatitis (CP): Definition &amp; Paradigm Shift</strong></summary>
            <div>
                <ul><li>CP: Historically defined as irreversible inflammatory condition → varying exocrine/endocrine dysfunction.</li><li>New Paradigm: Focus on diagnosing underlying pathologic process early; holistic management → Δ natural course, minimize adverse effects.</li></ul>
                
        <details>
            <summary><strong>Mechanistic Definition (2016)</strong></summary>
            <div>
                <ul><li>Pathologic fibroinflammatory syndrome of pancreas.</li><li>Occurs in individuals w/ genetic, environmental, and/or other risk factors.</li><li>Develop persistent pathologic responses to parenchymal injury/stress.</li></ul>
                
        <details>
            <summary><strong>End-Stage Disease Characteristics</strong></summary>
            <div>
                <ul><li>Pancreatic atrophy; fibrosis; pain syndromes.</li><li>Duct distortion &amp; strictures; calcifications.</li><li>Pancreatic exocrine dysfunction; pancreatic endocrine dysfunction.</li><li>Dysplasia.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Precision Medicine Approach</strong></summary>
            <div>
                <ul><li>Complex gene + environmental interactions in individual patient.</li><li>Focus on early signs/symptoms of disease.</li><li>&#x27;Bottom-up&#x27; approach for complex disorders w/ multiple etiologies, modifiers, complications, outcomes.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Traditional Clinicopathologic Definition (Pre-2016)</strong></summary>
            <div>
                <ul><li>Chronic inflammation + irreversible fibrosis w/o infection.</li><li>Primary challenge: Obtaining pancreatic tissue (gold standard) due to high risk/benefit ratio of biopsies.</li></ul>
                
        <details>
            <summary><strong>Marseille Consensus Conferences (1963-1989)</strong></summary>
            <div>
                <ul><li>Defined CP based on clinical, functional, histologic evidence.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cambridge Definition (1984)</strong></summary>
            <div>
                <ul><li>Clinically useful alternative to biopsy; used ERCP scoring system as surrogate for tissue.</li><li>Defined as continuing inflammatory disease of pancreas → irreversible morphological change, typically causing pain and/or permanent loss of function.</li><li>Served as basis for imaging approaches &amp; guidelines for 3 decades.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Limitations of Traditional Framework</strong></summary>
            <div>
                <ul><li>Results in years of delay between symptom onset &amp; diagnosis.</li><li>Usually fails to identify/address underlying etiology.</li><li>Cannot predict clinical course or direct preventative treatments.</li><li>Limited to symptomatic/supportive care &amp; replacement of lost gland function.</li><li>Early CP (where targeted therapy is effective) cannot be diagnosed (requires irreversible morphologic change).</li></ul>
                
        <details>
            <summary><strong>Fibrosis Correlation</strong></summary>
            <div>
                <ul><li>Degree of fibrosis correlates poorly w/ pain, EPI, DM, progressive disease, or cancer risk.</li><li>These are primary concerns of clinical care.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Distinction of Pancreatic Conditions</strong></summary>
            <div>
                <ul><li>Dysfunction: Dynamic term; variation in entity&#x27;s action that deviates from normal negatively.</li><li>Disorder: Disruption of normal functions of specialized cells/systems → abnormal signs, symptoms, biomarkers, responses.</li><li>Disease: Abnormal condition defined by consensus criteria (abnormal signs/symptoms, biomarkers, typical pathologic features).</li></ul>
                
        <details>
            <summary><strong>Example: CFTR Gene</strong></summary>
            <div>
                <ul><li>Genetic mutation in CFTR gene locus → variations in RNA expression/splicing, or Δ amino acid sequence → defective processing, trafficking, or channel opening.</li><li>Dysfunction may be tolerated by adaptive mechanisms/limited cell stress.</li><li>Pancreatitis-related disorder: Protein dysfunction → pancreatic duct cell fails to respond normally to stimulation/stress → duct cell dysfunction.</li><li>When compensatory threshold exceeded → internal/external stress/injury signals → clinical signs/symptoms (e.g., acute pancreatitis episode).</li><li>Pancreatic diseases: Conditions w/ pathology (e.g., AP, RAP, CP, cystic fibrosis).</li><li>Precision medicine: Focus on determining dysfunction/disorder → targeted therapy to prevent progression to clinicopathologic-defined disease.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Presentation of CP</strong></summary>
            <div>
                <ul><li>Most common symptom: Abdominal pain.</li><li>Other symptoms: Exocrine pancreatic insufficiency (EPI), diabetes mellitus (DM).</li><li>Development rates of EPI/DM are highly variable.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Causes &amp; Risk Factors of CP</strong></summary>
            <div>
                <ul><li>Most common causes: Toxins (alcohol, tobacco use), genetic polymorphisms, recurrent attacks of acute pancreatitis (RAP).</li><li>Note: Many patients have no history of acute pancreatitis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis of CP</strong></summary>
            <div>
                <ul><li>Historically difficult due to debate over gold-standard test.</li><li>Often made using combination of modalities: exposure risk, underlying predisposition, cross-sectional imaging, direct/indirect pancreatic function tests.</li><li>Most useful diagnostic test: Careful history &amp; physical examination → pretest probability &amp; clinical suspicion integral.</li></ul>
                
        <details>
            <summary><strong>Recommendation 1: First-Line Imaging</strong></summary>
            <div>
                <ul><li>We recommend CT or MRI for the first-line diagnosis of CP.</li><li>Either test should be the first choice for CP diagnosis.</li><li>EUS should be used only if diagnosis is in question after cross-sectional imaging (due to invasiveness &amp; lack of specificity).</li><li>Strength: Strong recommendation, low quality of evidence.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>No RCTs comparing cross-sectional imaging w/ EUS for CP diagnosis.</li><li>Systematic review/meta-analysis (43 studies, 3460 patients): Sensitivity estimates for EUS (81%), MRI (78%), CT (75%) did not differ significantly.</li><li>Specificity estimates: EUS (90%), ERCP (94%), CT (91%), MRI (96%), US (98%) were comparable.</li><li>Limitation: Not all studies included histologic gold standard.</li><li>Rationale: Vast discrepancy in cost, availability, invasiveness, objectivity favors cross-sectional imaging as first-line.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Demonstrating typical morphologic changes is critical component of CP definition (imaging is surrogate for histology).</li><li>Cross-sectional imaging: Familiar, initial test for diagnosis.</li><li>EUS: Use if diagnosis still in doubt after cross-sectional imaging, or concern about &#x27;minimal change disease&#x27; (CP w/o fibrosis evidence on cross-sectional imaging).</li><li>No specific EUS scoring system or number/types of criteria recommended.</li><li>CP remains a clinical diagnosis: Integrate clinical scenario, risk factors, exclusion of other diseases.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation 2: Secretin-Enhanced MRCP (s-MRCP)</strong></summary>
            <div>
                <ul><li>We suggest performing s-MRCP when CP diagnosis following cross-sectional imaging or EUS is not confirmed and clinical suspicion remains high.</li><li>Strength: Conditional recommendation, low quality of evidence.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>s-MRCP: Better visualization of main- &amp; side-branch ducts by stimulating bicarbonate release from pancreatic duct cells.</li><li>Allows quantification of duodenal filling → correlates w/ CP severity &amp; pancreatic exocrine function.</li><li>No RCTs evaluating s-MRCP for CP diagnosis.</li><li>Systematic review (69 articles, 15 reviews): Dynamic thick-slab 2D MRCP most used sequence (86%). Main pancreatic duct diameter (75%) &amp; visual grading of duodenal filling (67%) most evaluated features.</li><li>Smaller studies suggest diagnostic value in children w/ idiopathic CP &amp; for minimal change disease.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Use if cross-sectional imaging &amp; EUS are not diagnostic of CP.</li><li>Identifies subtle ductal abnormalities (dilated branches, ectatic duct) consistent w/ CP imaging criteria.</li><li>Structural imaging is a biomarker of pancreas morphology, most sensitive to changes from fibrosis w/ duct distortion &amp; calcifications.</li><li>Diagnosis of CP should not be made solely on s-MRCP findings or other imaging modalities.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concept 1: Pancreatic Function Testing (PFT)</strong></summary>
            <div>
                <ul><li>PFT is important for diagnosing EPI; its role in establishing CP diagnosis is complementary.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>Controversy surrounds PFT use for CP diagnosis.</li><li>PFTs diagnose EPI; most CP patients lack clinically significant EPI.</li><li>Sensitivity of PFT for CP diagnosis is low.</li><li>Significant loss of function (&gt;90%) required for clinical symptoms of steatorrhea, azotorrhea, vitamin deficiency.</li><li>EPI represents imbalance in 4 domains: nutritional intake, enzyme delivery, intestinal adaptation, nutritional needs.</li><li>No RCTs, systematic reviews, or meta-analyses on PFT for CP diagnosis.</li><li>Use as ancillary test for CP diagnosis.</li></ul>
                
        <details>
            <summary><strong>Types of Pancreatic Function Tests (Table 4 Summary)</strong></summary>
            <div>
                <ul><li>Hormonal (Direct) Tests:</li><li>CCK stimulation test (acinar cell function, trypsin/lipase): Direct, detects subtle EPI. Disadvantages: cumbersome, not widely available, specialized lab, patient discomfort (Dreiling tube), 2-3 hr test.</li><li>Secretin stimulation test (ductal cell function, bicarbonate): Direct, performed endoscopically, uses lab autoanalyzer, 60 min test. Disadvantages: not widely available, prone to error, risk/cost of endoscopy.</li><li>Non-Hormonal (Indirect) Tests:</li><li>Fecal elastase-1: Universally available, easily obtainable, non-invasive. Disadvantages: moderate sensitivity, limited specificity in diarrhea, limited use in mild disease.</li><li>13C-mixed triglyceride test: Easily obtainable, high sensitivity (90%). Disadvantages: not universally available, long test duration (4-6 hr).</li><li>Serum trypsinogen/trypsin: Universally available, easily obtainable, non-invasive, quantifiable for tracking function. Disadvantages: does not measure digestive tract enzymes, elevated w/ pancreatic pain.</li></ul>
                
        <details>
            <summary><strong>Fecal Elastase-1 Caveats</strong></summary>
            <div>
                <ul><li>Accuracy depends on cutoff.</li><li>&lt;200 mg/g stool: High false-positive rate.</li><li>&lt;100 mg/g stool: Improves specificity, lowers sensitivity.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Serum Trypsin/Trypsinogen</strong></summary>
            <div>
                <ul><li>Not typically performed due to reports of elevation in nonpancreatic pain syndromes &amp; poor correlation w/ imaging findings.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>EPI alone does not establish CP diagnosis (e.g., CFTR variants can cause ↓ bicarbonate secretion w/o tissue loss/morphologic change).</li><li>PFTs should be adjunctive test for patients w/ unestablished CP diagnosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation 3: Histological Examination</strong></summary>
            <div>
                <ul><li>We suggest histological examination as the gold standard to diagnose CP in high-risk patients when clinical &amp; functional evidence of CP is strong, but imaging modalities are inconclusive.</li><li>Strength: Conditional recommendation, very low quality of evidence.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>Considered when CP diagnosis cannot be made by cross-sectional imaging or EUS.</li><li>EUS-guided fine-needle biopsy techniques make tissue acquisition safer/easier.</li><li>Sensitivity of histologic evaluation for CP (when tissue available) often no better than chance compared to morphologic evaluation.</li><li>Limitations: Sampling error, biopsy complications, patchy nature of inflammatory changes, subjective histologic interpretation.</li><li>No RCTs, systematic reviews, or meta-analyses treating histology as diagnostic gold standard.</li><li>Value: Most important for ruling out CP.</li><li>Consider only in high-risk patients after clinical, functional, and imaging tests are inconclusive, w/ thoughtful informed consent.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Under current clinicopathologic approach, histology is gold standard to diagnose CP; often used to &#x27;rule out&#x27; CP.</li><li>Both imaging &amp; histology are biomarkers of underlying disorder, not necessarily true CP → sensitivity of histology for diagnosis is low.</li><li>As mechanistic model develops, histology likely ↓ importance in CP diagnosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Etiology of CP</strong></summary>
            <div>
                <ul><li>Identifying the cause of CP is crucial for management and prognosis.</li></ul>
                
        <details>
            <summary><strong>Key Concept 2: Comprehensive Risk Factor Review</strong></summary>
            <div>
                <ul><li>In patients w/ clinical features of CP, comprehensive review of all risk factors should be performed.</li><li>Provides information on underlying mechanisms.</li><li>Identifies fixed &amp; modifiable risk factors.</li><li>Identifies potential targets for therapies.</li><li>Provides clinically relevant prognostic information.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>No RCTs, systematic reviews, or meta-analyses on order of testing for CP etiology.</li><li>TIGAR-O system: Categorizes etiology (Toxic-Metabolic, Idiopathic, Genetic, Autoimmune, Recurrent acute/severe pancreatitis, Obstructive); useful in international studies, recently revised.</li><li>M-ANNHEIM system: Similar multi-risk factor classification; adds info on disease activity/stage, evaluates impact/interaction of risk factors on CP course.</li><li>M-ANNHEIM provides diagnostic criteria for etiology, clinical/diagnostic stage, severity based on traditional clinicopathologic criteria.</li></ul>
                
        <details>
            <summary><strong>TIGAR-O Version 2.0 Pancreatitis System Risk/Etiology Checklist (Table 5 Summary)</strong></summary>
            <div>
                <ul><li>Toxic-metabolic: Alcohol-related (3-4 drinks/d, ≥5 drinks/d), Smoking (pack-years), Hypercalcemia (&gt;12.0 mg/dL or 3 mmol/L), Hypertriglyceridemia (fasting &gt;300 mg/dL; nonfasting &gt;500 mg/dL), Hypertriglyceridemic acute pancreatitis (history of &gt;500 mg/dL in first 72 hr), Medications, Toxins, CKD (stage 5-ESRD), Metabolic (e.g., DM w/ diagnosis date).</li><li>Idiopathic: Early onset (&lt;35 yr), Late onset (&gt;35 yr).</li><li>Genetic: Suspected/limited genotyping, Autosomal dominant (PRSS1 mutations), Autosomal recessive (CFTR, SPINK1), Complex genetics (modifier genes like PRSS1-PRSS1 locus, CLDN2 locus, hypertriglyceridemia genes).</li><li>AIP/steroid-responsive pancreatitis: AIP type 1 (IgG4-related), AIP type 2.</li><li>RAP and SAP: Acute pancreatitis (single episode w/ date), AP etiology (extrapancreatic: biliary, post-ERCP, traumatic, undetermined), RAP (number, frequency, dates).</li><li>Obstructive: Pancreas divisum, Ampullary stenosis, Main duct pancreatic stones, Widespread pancreatic calcifications, Main pancreatic duct strictures, Localized mass causing duct obstruction.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>M-ANNHEIM Scoring System for CP Severity (Table 6 Summary)</strong></summary>
            <div>
                <ul><li>Scores clinical features: Patient report of pain (0-4 points, from no pain w/o therapy to continuous pain), Pain control (0-4 points, from no medication to surgical intervention), Exocrine insufficiency (0-2 points, from absence to proven/marked steatorrhea), Endocrine insufficiency (0-4 points, absence of DM to presence of DM), Morphologic status on pancreatic imaging (Cambridge classification: 0-4 points, normal to marked), Severe organ complications (0-4 points, absence to irreversible complications).</li><li>Severity Index: Sum of points categorizes disease (M-ANNHEIM A: Minor 0-5, B: Increased 6-10, C: Advanced 11-15, D: Marked 16-20, E: Exacerbated &gt;20).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Initial approach: Thorough history &amp; physical exam, biomarker tests.</li><li>History: Previous AP episodes (TIGAR-O/M-ANNHEIM), DM onset, maldigestion/malnutrition, weight loss, bone health, renal disease, CF-associated organ diseases.</li><li>Family history: ≥3rd-degree relatives for pancreatitis, CF, DM, pancreatic cancer.</li><li>TIGAR-O checklist: Guides recording alcohol use, smoking, medications, toxins, DM, diet, key biomarkers (serum calcium, triglycerides, fat-soluble vitamins, nutrition analysis).</li><li>Imaging: Identifies obstructive etiologies (malformations, stones, tumors).</li><li>Genetic testing: Indicated if etiology unclear, family history of pancreatic diseases, disease persists after intervention (e.g., RAP after biliary clearance), or young patient (&lt;35 yrs).</li><li>Differential diagnosis: Autoimmune inflammation, islet cell-related fibrosis (long-standing DM), renal disease, immune-altering medications (cyclosporine), age-related atrophy/fibrosis, IPMN, acinar cell cystadenoma, desmoplastic response to neoplasm, inflammation upstream of duct-obstructing mass.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation 4: Genetic Testing</strong></summary>
            <div>
                <ul><li>We recommend genetic testing in patients w/ clinical evidence of a pancreatitis-associated disorder or possible CP where etiology is unclear, especially in younger patients.</li><li>Strength: Strong recommendation, low quality of evidence.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>Past 2 decades: Several genes associated w/ CP diagnosis.</li><li>No RCTs, systematic reviews, or meta-analyses on genetic testing for idiopathic CP.</li><li>Primary goal: Identify underlying pancreatitis-related disorders contributing to pathogenic process, assist decision-making, prevent irreversible CP.</li><li>Examples: CFTR variants (CFTR-related disorder or cystic fibrosis) presenting as RAP or CP → significant Δ in treatment strategy.</li><li>Genetic testing provides early info on etiology of pancreatitis-related disorders.</li><li>If etiology obscure: Determines dysfunctional genes, cell types, mechanisms.</li><li>This info drives confirmatory testing (e.g., sweat chloride for CFTR) &amp; places patient in high/low disease prevalence population → affects predictive value of biomarkers.</li><li>May not lead to immediate treatment but ends exhaustive, invasive, expensive diagnostic testing.</li><li>Informs decisions about radical therapy (e.g., TPIAT).</li><li>Value to patient: Resolution of poorly defined symptoms, connection to support networks, prognosis/comorbidities, family planning.</li><li>Limited value in end-stage CP (irreversible destruction) except for familial disorders, patient insight beyond alcohol/smoking, or research.</li></ul>
                
        <details>
            <summary><strong>Genetic Polymorphisms Implicated in CP (Table 7 Summary)</strong></summary>
            <div>
                <ul><li>Acinar Cell Dysfunction:</li><li>PRSS1 (cationic trypsinogen gene): Complex low penetrance; misfolding, ER stress → Recurrent AP &amp; CP.</li><li>CPA1 (carboxypeptidase A1 gene): Complex low penetrance; misfolding, ER stress → High relative risk of nonalcoholic CP.</li><li>CEL (carboxyl ester lipase): Autosomal dominant complex; misfolding, aggregations, ER stress → MODY-8 pancreatitis.</li><li>SPINK1 (serine protein inhibitor Kazal type 1): Autosomal recessive; loss of protein function due to blocked active site of trypsin; 2% of population; homozygotes w/ more severe disease.</li><li>CTRC (chymotrypsin C): Autosomal dominant; activated trypsin resistant to degradation → Associated w/ early-onset pancreatitis.</li><li>Ductal Cell Dysfunction:</li><li>CFTR (cystic fibrosis transmembrane conductance regulator): Autosomal recessive; loss of protein function due to failure of ductal bicarbonate secretion; &gt;2000 gene variants; widely divergent clinical presentation.</li><li>Disease-Modifying Genes:</li><li>CASR (calcium-sensing receptor gene): Autosomal recessive; loss of ability to regulate intracellular calcium; gain of function affects acinar cells, loss of function affects ductal cells.</li><li>CTRC (chymotrypsin C): Complex; low expression effect potentiated by smoking; pancreatitis when present w/ a trypsin-activating variant.</li><li>CLDN2 locus (Claudin-2 gene locus): Unknown; high risk w/ alcoholism; accelerates transition from RAP to CP.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Germline mutations testing: Not diagnostic of CP, but (i) identifies high prevalence population for pancreatitis-related disorders/CP → improves accuracy of less sensitive/specific biomarkers, and (ii) identifies dysfunctional mechanism underlying pathogenic processes.</li><li>Important for all ages: Therapies (e.g., CFTR-modulating drugs) can target mechanism, guiding drug/therapy selection.</li><li>Provides prognostic info for complex syndromes (e.g., TPIAT assessment) &amp; answers for patients.</li><li>Referral to genetic counselor: Recommended, but experienced non-geneticist clinicians can order/evaluate results.</li><li>Minimum testing for idiopathic CP: PRSS1, SPINK1, CFTR, CTRC gene mutation analysis.</li><li>Extended panels: &gt;dozen susceptibility/modifier genes, hypertriglyceridemia genes, pharmacogenetics available.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Natural History &amp; Clinical Symptoms of CP</strong></summary>
            <div>
                <ul><li>Primary clinical outcomes: Debilitating abdominal pain, fat-soluble vitamin deficiency (malnutrition, osteoporosis), pancreatic malignancy risk, endocrine insufficiency (DM).</li><li>Disease is irreversible at this stage; preventive/restorative therapy not possible.</li></ul>
                
        <details>
            <summary><strong>Key Concept 3: Predicting Progression to CP</strong></summary>
            <div>
                <ul><li>Identification of the disorder(s) underlying pancreatic inflammation is important in predicting progression to CP.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>No RCTs, systematic reviews, or meta-analyses specifically evaluating etiology of pancreatitis &amp; natural history of pain.</li><li>CP evolves over years → opportunities to intervene.</li><li>~60% of CP cases evolve from AP &amp; RAP.</li><li>~10% of AP &amp; 30% of RAP progress to CP.</li><li>Etiology plays major role: Progression from AP to CP is 2x faster w/ alcoholic etiologies vs. genetic/idiopathic; 5x faster than biliary AP.</li><li>Genetic modifiers strongly affect RAP → CP progression risk.</li><li>Painful CP: Previously suggested to improve over time (especially alcohol-induced), but not reproduced; generally accepted pain does not &#x27;resolve&#x27; or &#x27;burn out&#x27;.</li><li>Fat-soluble vitamin deficiency: Occurs in minority of CP patients due to ↓ oral intake (pain) &amp; malabsorption (limited enzyme production).</li><li>Prevalence of exocrine insufficiency: 40-75% in large natural history studies.</li><li>Risk highest in CP due to alcohol/tobacco use &amp; fibrocystic (tropical) pancreatitis.</li><li>Pancreatic adenocarcinoma risk: Relatively higher than general population, but likely lower than previously reported.</li><li>Genetic polymorphisms: Lifetime risk of pancreatic adenocarcinoma 5-10% in well-characterized at-risk patients.</li><li>Data limited to case series &amp; retrospective cohort studies.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Generally, specific CP etiology not proven to determine important clinical outcomes (rapid progression, EPI, severe pain, malignancy risk).</li><li>Exception: Autoimmune pancreatitis (pain not frequent complication) → etiology may determine outcomes/symptoms.</li><li>Identification of disorder causing pancreatic inflammation can be important in predicting CP progression.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concept 4: Development of Diabetes Mellitus (DM)</strong></summary>
            <div>
                <ul><li>Development of DM in CP is most likely related to duration of disease.</li><li>Other etiologic factors: BMI &amp; smoking status may incur an ↑ risk.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>Risk of pancreatic endocrine failure (type 3c DM) not demonstrated to result from any specific CP etiology.</li><li>Duration of disease: Likely most important etiologic risk factor for endocrine failure.</li><li>Tobacco use: May also play a role in DM development.</li><li>No RCTs, systematic reviews, or meta-analyses on endocrine dysfunction risk in CP.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Obese patients: More likely to have type 2 DM.</li><li>Advanced CP patients: More likely to have low BMI &amp; T3cDM from islet cell loss.</li><li>New-onset DM w/ weight loss: Potentially indicator of pancreatic ductal adenocarcinoma.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation 5: Alcohol Cessation</strong></summary>
            <div>
                <ul><li>We recommend alcohol cessation in patients w/ CP.</li><li>Strength: Strong recommendation, very low quality of evidence.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>No RCTs, systematic reviews, or meta-analyses on alcohol cessation altering CP pain natural history.</li><li>Case series: Discontinuing alcohol improves CP pain, but doesn&#x27;t necessarily alter progression to endocrine/exocrine dysfunction.</li><li>1 RCT: Alcohol cessation counseling in acute alcoholic pancreatitis patients ↓ hospitalizations &amp; pain attacks.</li><li>Alcohol cessation counseling recommended for CP patients, though extent of altering natural history is unknown.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Despite low-quality evidence, strict alcohol avoidance should be cornerstone of CP treatment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation 6: Smoking Cessation</strong></summary>
            <div>
                <ul><li>We recommend smoking cessation in patients w/ CP.</li><li>Strength: Strong recommendation, very low quality of evidence.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>Smoking cessation challenging for CP patients.</li><li>Smoking tobacco: Widely believed CP risk factor, but only single-center studies available.</li><li>No RCTs, systematic reviews, or meta-analyses on smoking cessation benefiting CP natural history.</li><li>Case series: ↓ pancreatic calcification progression w/ smoking cessation at CP diagnosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Despite low-quality evidence, strict smoking avoidance should be cornerstone of CP treatment.</li><li>Recognize low long-term success rate of smoking cessation.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concept 5: Pancreatic Malignancy Screening</strong></summary>
            <div>
                <ul><li>There is a lack of evidence to suggest that performing screening examinations on patients w/ CP to detect pancreatic malignancy is beneficial.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>Very little quality evidence for screening all CP patients, even high-risk ones.</li><li>Overall prevalence of pancreatic malignancy ↑ in CP patients.</li><li>No RCTs, systematic reviews, or meta-analyses support screening this population.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>No definitive benefit to screen CP patients for pancreatic ductal adenocarcinoma.</li><li>Reasons: Invasive/costly testing, inherent difficulty due to CP structural changes, inability to alter natural history even w/ early detection.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management of Pain in CP</strong></summary>
            <div>
                <ul><li>Pain is a major symptom in CP, requiring careful management strategies.</li></ul>
                
        <details>
            <summary><strong>Key Concept 6: Elective Interventions &amp; Alcohol Use</strong></summary>
            <div>
                <ul><li>Performing elective interventional procedures on patients actively using alcohol should be considered cautiously.</li><li>Patients requiring urgent/emergent procedures for CP complications should be considered separately.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>No RCTs, systematic reviews, or meta-analyses specifically addressing this issue.</li><li>Medical perspective: Aggressive endoscopic/surgical interventions may be ill-advised if ongoing alcohol abuse exacerbates CP pain.</li><li>Alcohol cessation could negate need for some interventions.</li><li>Social perspective: Patients continuing alcohol after education still warrant care; encourage cessation via counseling/programs.</li><li>Urgent interventions should be performed regardless of alcohol use.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Elective interventional procedures (e.g., celiac plexus interventions) w/ caution in active alcohol users.</li><li>Urgent interventions: Perform due to medical necessity.</li><li>Patients making good faith efforts to stop/reduce alcohol: Evaluate for interventional procedures case-by-case, recognizing cessation difficulties &amp; need to treat symptoms.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation 7: Surgical vs. Endoscopic Drainage for Obstructive CP</strong></summary>
            <div>
                <ul><li>We recommend surgical intervention over endoscopic therapy in patients w/ obstructive CP for long-term pain relief if first-line endoscopic approaches to pancreatic drainage have been exhausted or unsuccessful.</li><li>Strength: Strong recommendation, moderate quality of evidence.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>Duct obstruction: Pancreatic duct stones, strictures, or combination.</li><li>Endoscopic decompressive procedures: ERCP w/ sphincterotomy, stone clearance, stricture dilation, stenting; interventional EUS procedures (transluminal stent).</li><li>Surgical decompressive procedures: Puestow, Frey, Beger procedures (may include partial pancreatectomy).</li><li>No RCT/systematic review data reliably report if successful/unsuccessful endoscopic decompression predicts successful drainage surgery.</li><li>Cahen et al. (2007 RCT, 39 patients): Surgery group had lower pain scores (P &lt; 0.001) &amp; better physical health (P = 0.003).</li><li>24-month follow-up: Complete/partial pain relief in 32% (endoscopic) vs. 75% (surgical) (P = 0.007).</li><li>Complication rates, length of stay, pancreatic function similar.</li><li>Endoscopic group required more interventions (median 8 vs. 3, P &lt; 0.001).</li><li>Long-term follow-up (79 months): 68% of original endoscopic group underwent additional drainage vs. 5% surgical (P = 0.001).</li><li>47% of endoscopic patients ultimately had surgery.</li><li>Mean difference in pain scores no longer significant (39 vs. 22; P = 0.12), but surgery superior for pain relief (80% vs. 38%; P = 0.042).</li><li>Overall QoL &amp; pancreatic function not different.</li><li>Older study (Díte et al. 2003, 140 patients): Similar initial success rates, but complete pain absence lower in both groups; more common w/ surgery (37% vs. 14%). Partial relief equivalent (49% vs. 51%).</li><li>Surgery group gained more weight; new-onset DM equal in both.</li><li>Various studies compare different surgical drainage procedures; no clear superiority.</li><li>Note: Many studies are older; interventional endoscopic approaches more widely performed now. Newer comparative studies warranted.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Surgical approaches: Better long-term pain relief than endoscopic, but rarely first-line.</li><li>Many surgeons operate only after endoscopic approaches exhausted/unsuccessful.</li><li>Reasonable to perform endoscopic drainage (ERCP/EUS) as first-line for symptomatic, obstructed pancreatic duct.</li><li>Surgery reserved for treatment failures or those unwilling to undergo multiple endoscopic treatments.</li><li>Means of ductal decompression (e.g., lithotripsy) at endoscopist&#x27;s discretion based on local expertise.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation 8: Antioxidant Therapy for Pain</strong></summary>
            <div>
                <ul><li>We suggest considering antioxidant therapy for CP w/ pain, although benefit of pain reduction is likely limited.</li><li>Strength: Conditional recommendation, moderate quality of evidence.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>Mechanism: Reduce oxidative stress, anti-inflammatory effect.</li><li>Could be alternative to narcotics.</li><li>RCT (2009): 5 antioxidant agents (selenium, ascorbic acid, b-carotene, a-tocopherol, methionine) vs. placebo.</li><li>Antioxidant group: Significantly fewer painful days/month, less analgesic use, more pain-free patients.</li><li>Double-blind RCT (70 patients, alcohol-induced CP): Antioxidant therapy (selenium yeast, D-a-tocopherol acetate, ascorbic acid, L-methionine, b-carotene) vs. placebo.</li><li>No statistically significant difference in pain scores at 6 months.</li><li>Opiate use, hospital admissions, outpatient visits similar.</li><li>Conclusion: Antioxidants did not improve pain/QoL in alcohol-induced CP.</li><li>Multimodality treatment (incl. antioxidants + interventional therapies): Resulted in long-term pain relief in non-RCT series.</li><li>Two meta-analyses (9 &amp; 12 trials): Antioxidants appeared to reduce pain, but effect size was small.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Data limited, scientific plausibility questionable, not FDA-regulated.</li><li>Appear safe, may reduce pain.</li><li>Consider for clinical use, especially early in disease course.</li><li>Optimal type/dosage unclear; clinical trials generally include selenium, ascorbic acid, b-carotene, methionine.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concept 7: Opiates for Pain</strong></summary>
            <div>
                <ul><li>Opiates may be considered to treat painful CP only in patients in whom all other reasonable therapeutic options have been exhausted.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>Debated for decades.</li><li>Arguments for: Efficacy, low cost.</li><li>Arguments against: Addiction risk, abuse, tolerance; concerns about prescribing to patients w/ substance abuse history (alcoholism); side effects (constipation).</li><li>Few quality studies; no RCTs, systematic reviews, or meta-analyses.</li><li>Trial (18 CP patients): Transdermal fentanyl vs. sustained-release morphine (randomized cross-over).</li><li>Transdermal fentanyl not ideal: Dosage ↑ 50% above manufacturer rec, significantly more rescue morphine needed.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Avoid opiates if possible due to addiction, abuse, tolerance risks.</li><li>Justified for refractory pain if other modalities fail.</li><li>Patients previously prescribed opiates: Encourage transition to other medications.</li><li>Prescribing clinician (gastroenterologist/PCP/pain management/palliative care): Knowledgeable about disease natural history, monitors symptoms/response, adheres to universal precautions for safe prescribing (screening for opiate use disorder, patient-provider agreement, annual urine drug screen, annual prescription system check, addiction counseling, wrap-around services).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation 9: Pancreatic Enzyme Supplements for Pain</strong></summary>
            <div>
                <ul><li>We do not suggest the use of pancreatic enzyme supplements to improve pain in CP.</li><li>Strength: Conditional recommendation, low quality of evidence.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>PERT established for symptomatic EPI, but role for pain less clear.</li><li>Plausible for EPI-related pain (cramping, diarrhea), but unclear for primary pancreatic pain (inflammation, ductal stones).</li><li>Older study (26 CP patients): Enteric-coated enzymes vs. placebo (4-month cross-over).</li><li>No difference found; enzymes not beneficial for pain.</li><li>Cochrane review (2009, 10 RCTs, 361 patients): Equivocal result for enzymes treating pain; studies of less than ideal quality.</li><li>Meta-analysis (5 randomized studies): Failed to show meaningful effect on pain relief; 1 study showed benefit for non-enteric-coated enzymes.</li><li>Meta-analysis (6 randomized, double-blind, placebo-controlled trials): Failed to show significant benefit on CP-associated pain.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Do not use pancreatic enzyme therapy for pain control due to expense &amp; general lack of efficacy.</li><li>Patients w/ EPI: Usually derive benefit from PERT for discomfort (abdominal cramping, etc.).</li><li>If patients feel pain improved on PERT (especially non-enteric-coated formulations w/ biologic plausibility): Reasonable to continue due to low risk &amp; lack of other low-risk analgesic alternatives.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation 10: Celiac Plexus Block (CPB) for Pain</strong></summary>
            <div>
                <ul><li>We suggest considering celiac plexus block for treatment of pain in CP.</li><li>Strength: Conditional recommendation, very low quality of evidence.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>CPB: Injection of pharmaceuticals (local anesthetic + steroid, e.g., bupivacaine + triamcinolone) into/around celiac ganglia.</li><li>Performed via endoscopy, interventional radiology, or surgery.</li><li>Advantages: Single treatment → pain reduction/relief for 3-6 months, may reduce/eliminate oral analgesia, quick, repeatable.</li><li>Disadvantages: Procedure risks (bleeding, allergic reaction), sedation risks/needs.</li><li>Generally similar efficacy regardless of physician type (endoscopist, radiologist, surgeon); decision based on experience/availability.</li><li>Meta-analysis (efficacy of CPB): Favored EUS-guided injections over percutaneous, but percutaneous data limited.</li><li>Reported pain relief range: 25-96%; median response rate: EUS-guided 68%, percutaneous 61%.</li><li>Overall: CPB effective at relieving CP pain.</li><li>Rationale for recommendation: Numerous studies, but most compared EUS vs. percutaneous; clinical success varied significantly. &#x27;Selected patients&#x27; highlights that many studies show no significant benefit in some CP patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>CPB: Relatively low-risk, opioid-free method to reduce refractory pain in certain CP patients.</li><li>Meaningful symptom reduction possible for some, but unclear which patients benefit most.</li><li>Repeatable on &#x27;as-needed&#x27; basis, generally ≥3 months apart if initial intervention was beneficial.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concept 8: Total Pancreatectomy with Islet Autotransplantation (TPIAT)</strong></summary>
            <div>
                <ul><li>TPIAT should be reserved for highly selected patients w/ refractory chronic pain in whom all other symptom control measures have failed.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>Increasingly used for refractory painful CP.</li><li>Offered at selected centers.</li><li>Outcomes/effectiveness not subjected to RCTs, systematic reviews, or meta-analyses.</li><li>Data: Exclusively case series &amp; cohort studies → limited efficacy statements.</li><li>Critical need for comparative effectiveness studies on clinical outcomes.</li><li>Patients considering TPIAT: Evaluate at expert center w/ multidisciplinary evaluation.</li><li>Apprise patients of risks: Type 3c DM, potential lifelong intestinal dysmotility disorders.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Consider only after all medical treatment options exhausted.</li><li>Resection procedures for painful CP should include discussion of islet cell replacement therapy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concept 9: Experimental Treatment Modalities</strong></summary>
            <div>
                <ul><li>Experimental treatment modalities should be limited to use in the context of a clinical research trial.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>For refractory CP pain: Spinal cord nerve stimulation, transmagnetic brain stimulation, direct radiation therapy to pancreatic bed.</li><li>Data: Limited to small case series &amp; retrospective cohort studies.</li><li>Recommendation: Limit use to clinical research trials.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Patients w/ debilitating CP where medical/surgical interventions failed: Consider referral to expert center offering experimental therapies.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management of Exocrine Pancreatic Insufficiency (EPI) in CP</strong></summary>
            <div>
                <ul><li>EPI is a common complication of CP, leading to malnutrition and other issues.</li></ul>
                
        <details>
            <summary><strong>Recommendation 11: Pancreatic Enzyme Replacement Therapy (PERT)</strong></summary>
            <div>
                <ul><li>We suggest PERT in patients w/ CP and EPI to improve the complications of malnutrition.</li><li>Strength: Conditional recommendation, low level of evidence.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>Benefits of PERT: Symptom reduction, weight gain, fat absorption improvement, fat-soluble vitamin/trace element level improvement, reduction in maldigestion consequences (e.g., bone fracture risk), QoL improvement, mortality reduction.</li><li>Primary outcome for RCTs/FDA approval: Coefficient of fat absorption (CFA) over 72 hours.</li><li>FDA guidance: Clinically meaningful decrease in stool fat ≥30% (for CFA &lt;40%), CFA must ↑ ≥10%; studies ≥200 patients over 6 months (or 100 over 1 year).</li><li>Normal CFA: &gt;93% (≤7% dietary fat lost in stool).</li><li>17 randomized trials on PERT in CP (12 cross-over, 5 parallel).</li><li>Varied: Enteric-coated, non-enteric-coated, microtablets, granules; daily dosage (lipase USP/day) &lt;50,000 to &gt;700,000.</li><li>Some compared PERT products/dosages, others PERT vs. placebo.</li><li>Timing of ingestion varied (before/during meals); some added H2 inhibitor/PPI.</li><li>Cochrane review (2009, 10 RCTs, 361 patients): No identifiable improvement in pain or analgesic use.</li><li>Significantly reduced fecal fat; non-significant trend to weight/QoL improvement.</li><li>Conclusion: Data equivocal, urged additional studies.</li><li>Recent meta-analysis (17 trials): 14 trials on CFA.</li><li>PERT improved CFA vs. baseline significantly (83.7% ± 6.0 on PERT vs. 63.1 ± 15.0 baseline, P &lt; 0.00001).</li><li>Fecal nitrogen excretion &amp; stool weight also reduced (P &lt; 0.001).</li><li>Some studies: PERT improved flatulence &amp; fecal consistency.</li><li>7 studies compared PERT w/ placebo: PERT ↑ CFA vs. placebo (83.2 ± 5.5 vs. 67.4 ± 7.0, P = 0.0001, high heterogeneity I2 = 86%).</li><li>4 studies analyzed high-dose vs. low-dose PERT: Slightly higher CFA w/ lipase &gt;60,000 units daily (not significant).</li><li>Conclusion: PERT improved fat &amp; protein absorption vs. baseline or placebo.</li><li>Original studies: Max follow-up 2 months.</li><li>Long-term follow-up studies: Significant improvement in nutritional parameters, weight, symptoms, QoL.</li><li>No data on PERT preventing bone fracture.</li><li>Retrospective studies: EPI may have detrimental effect on mortality, but no data on PERT improving this condition.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Suspect EPI: Long-standing CP, weight loss, malnutrition, diarrhea, steatorrhea, osteoporosis, osteopenia.</li><li>Clinical suspicion often sufficient for diagnosis w/o formal fecal fat measurement; titrate enzymes to improve symptoms.</li><li>Abnormal fecal elastase: Most easily available diagnostic test.</li><li>Therapy: Adequate dosage (≥40,000-50,000 USP units of lipase w/ each meal) administered during meal.</li><li>Baseline &amp; periodic measurement of fat-soluble vitamin levels &amp; bone density are appropriate.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concept 10: Periodic Malnutrition Evaluation</strong></summary>
            <div>
                <ul><li>Patients w/ CP should have periodic evaluation for malnutrition, including tests for osteoporosis and fat-soluble vitamin deficiency.</li></ul>
                
        <details>
            <summary><strong>Summary of Evidence</strong></summary>
            <div>
                <ul><li>Testing for malnutrition consequences frequently performed, but no RCTs, systematic reviews, or meta-analyses provide evidence.</li><li>Single-center studies: ↑ risk of osteoporosis &amp; subsequent fracture risk in CP patients.</li><li>1 RCT: Intramuscular vs. oral vitamin D for sufficiency in CP; intramuscular more efficacious.</li><li>No studies on most appropriate test for bone loss.</li><li>CP patients at risk for fat-soluble vitamin deficiency (A, D, E, K), zinc, magnesium deficiency, regardless of proven EPI.</li><li>Degree of abnormality likely corresponds to EPI degree.</li><li>No RCTs, systematic reviews, or meta-analyses on testing for these deficiencies or dietary interventions in CP.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Practical Clinical Approach</strong></summary>
            <div>
                <ul><li>Despite low-quality evidence, periodic evaluation of fat-soluble vitamin &amp; zinc deficiency should be considered due to higher fracture risk &amp; ↑ malnutrition incidence.</li><li>Advise small, frequent meals w/o fat restriction.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
